Browse Studies — Arctuva

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Background: People with neurofibromatosis 1 (NF1) who have plexiform neurofibromas (pNFs) can have pain that affects their daily lives. This study aims to imp…

Neurofibromatosis 1Plexiform Neurofibromas

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT02544022

Phase 1

A Phase 1/1b/2 Study of Cabozantinib in Combination With Selumetinib for Plexiform Neurofibroma in Adults and Adolescents With Neurofibromatosis Type 1

Based on the clinical activity of both selumetinib and cabozantinib as monotherapies in clinical trials, the demonstrated activity of these agents in reduced d…

Neurofibromatosis 1Plexiform Neurofibroma

Estimated

~$10 – $7,500

Girish Dhall, MDNCT06502171

Phase 2

Phase 2 Trial of Selumetinib for the Prevention of Plexiform Neurofibroma Growth and Morbidity in Neurofibromatosis Type 1

Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and old…

Neurofibromatosis 1Plexiform Neurofibroma

Estimated

~$10 – $6,250

University of Alabama at BirminghamNCT06188741

Phase 1

A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas

The main purpose of this clinical trial is to test PAS-004 in people with at least one symptomatic plexiform neurofibroma due to Neurofibromatosis Type 1 (NF1)…

NF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more

Estimated

~$10 – $8,750

Pasithea Therapeutics Corp.NCT06961565